# Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

> **NCT04735263** · PHASE2 · RECRUITING · sponsor: **Massachusetts Eye and Ear Infirmary** · enrollment: 21 (estimated)

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **DRUG:** Atorvastatin 80mg

## Key facts

- **NCT ID:** NCT04735263
- **Lead sponsor:** Massachusetts Eye and Ear Infirmary
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-04
- **Primary completion:** 2027-04-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04735263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04735263, "Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04735263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*